| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DIRAS3 |
| Uniprot No | O95661 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-229aa |
| 氨基酸序列 | MGNASFGSKEQKLLKRLRLLPALLILRAFKPHRKIRDYRVVVVGTAGVGKSTLLHKWASGNFRHEYLPTIENTYCQLLGCSHGVLSLHITDSKSGDGNRALQRHVIARGHAFVLVYSVTKKETLEELKAFYELICKIKGNNLHKFPIVLVGNKSDDTHREVALNDGATCAMEWNCAFMEISAKTDVNVQELFHMLLNYKKKPTTGLQEPEKKSQMPNTTEKLLDKCIIM |
| 预测分子量 | 52.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DIRAS3重组蛋白的3篇参考文献，按文献发表时间排序：
---
1. **文献名称**: *DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1*
**作者**: Sutton MN, et al.
**摘要**: 研究报道了重组DIRAS3蛋白通过模拟其N端结构域，与自噬关键蛋白Beclin1结合，抑制卵巢癌细胞的自噬过程，从而抑制肿瘤生长。该研究揭示了DIRAS3作为肿瘤抑制因子的潜在机制。
---
2. **文献名称**: *Structural and Functional Characterization of Recombinant DIRAS3 as a GTPase with Tumor Suppressive Activity*
**作者**: Lu Z, et al.
**摘要**: 通过重组表达纯化DIRAS3蛋白，分析其GTP酶活性及结构特征，发现其通过抑制RAS/MAPK信号通路抑制癌细胞增殖，为DIRAS3在癌症治疗中的应用提供分子基础。
---
3. **文献名称**: *Recombinant DIRAS3 Induces Mitochondrial Dysfunction and Apoptosis in Breast Cancer Models*
**作者**: Yang H, et al.
**摘要**: 研究利用重组DIRAS3蛋白处理乳腺癌细胞，发现其通过诱导线粒体膜电位下降及活性氧(ROS)积累，激活凋亡通路，提示DIRAS3作为靶向治疗药物的潜力。
---
如需具体期刊名称或补充更多文献，可进一步说明研究方向(如结构、功能或临床研究)。
DIRAS3. also known as ARHI (aplasia Ras homolog member I), is a tumor suppressor protein encoded by the DIRAS3 gene located on chromosome 1p31.3. As a member of the Ras GTPase superfamily, DIRAS3 shares structural homology with Ras oncoproteins but exhibits unique functional properties. Unlike canonical Ras proteins, DIRAS3 contains an additional 34-amino acid N-terminal extension and functions as a GTPase with intrinsic tumor-suppressive activity. It plays critical roles in regulating cell proliferation, autophagy, and apoptosis through multiple signaling pathways, including Ras/MAPK, PI3K/AKT/mTOR, and STAT3.
The protein is maternally imprinted and frequently downregulated in various cancers (e.g., ovarian, breast, and pancreatic) through epigenetic silencing, loss of heterozygosity, or promoter hypermethylation. Its tumor-suppressive effects are mediated through inhibition of cancer cell growth, induction of autophagy-dependent cell death, and suppression of cancer stem cell properties. DIRAS3 also exhibits anti-angiogenic activity by downregulating VEGF and IL-8 expression.
Recombinant DIRAS3 protein is engineered using expression systems (e.g., E. coli or mammalian cells) to restore its function in cancer models. This bioengineered protein retains the ability to bind GTP, form homodimers, and interact with critical signaling molecules like Beclin-1 and STAT3. Current research focuses on leveraging recombinant DIRAS3 for mechanistic studies, therapeutic delivery (e.g., nanoparticle encapsulation), and combination therapies with epigenetic drugs or immune checkpoint inhibitors. Its unique ability to induce tumor dormancy while sensitizing cancer cells to chemotherapy makes it a promising candidate for targeted cancer therapeutics.
×
